CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today the promotion of Robert Gallotto to chief business officer. This appointment reflects Alnara’s growing operations as the company prepares to submit a new drug application (NDA) and commercialize liprotamase, a novel, oral, porcine-free pancreatic enzyme replacement therapy (PERT) that has already completed a Phase 3 efficacy trial.
